PortfoliosLab logoPortfoliosLab logo
LGND vs. GD
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LGND vs. GD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ligand Pharmaceuticals Incorporated (LGND) and General Dynamics Corporation (GD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, LGND achieves a 23.98% return, which is significantly higher than GD's 0.99% return. Over the past 10 years, LGND has underperformed GD with an annualized return of 7.10%, while GD has yielded a comparatively higher 11.57% annualized return.


LGND

1D
0.70%
1M
2.64%
YTD
23.98%
6M
21.43%
1Y
129.02%
3Y*
46.01%
5Y*
15.23%
10Y*
7.10%

GD

1D
-0.17%
1M
-3.45%
YTD
0.99%
6M
0.56%
1Y
24.34%
3Y*
19.67%
5Y*
14.14%
10Y*
11.57%
*Multi-year figures are annualized to reflect compound growth (CAGR)

LGND vs. GD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
LGND
Ligand Pharmaceuticals Incorporated
23.98%76.45%50.03%6.92%-56.75%55.31%-4.64%-23.15%-0.90%34.76%
GD
General Dynamics Corporation
0.99%30.39%3.52%7.13%21.69%43.77%-13.14%14.80%-21.34%19.85%

Correlation

The correlation between LGND and GD is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.22

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Nov 19, 1992

0.20

Fundamentals

Market Cap

LGND:

$4.66B

GD:

$92.38B

EPS

LGND:

$7.57

GD:

$15.92

PE Ratio

LGND:

30.96

GD:

21.17

PEG Ratio

LGND:

0.27

GD:

2.68

PS Ratio

LGND:

17.32

GD:

1.71

PB Ratio

LGND:

4.67

GD:

3.54

Total Revenue (TTM)

LGND:

$274.48M

GD:

$53.81B

Gross Profit (TTM)

LGND:

$221.02M

GD:

$7.48B

EBITDA (TTM)

LGND:

$253.90M

GD:

$6.26B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LGND vs. GD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LGND
LGND Risk / Return Rank: 9595
Overall Rank
LGND Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
LGND Sortino Ratio Rank: 9494
Sortino Ratio Rank
LGND Omega Ratio Rank: 9393
Omega Ratio Rank
LGND Calmar Ratio Rank: 9797
Calmar Ratio Rank
LGND Martin Ratio Rank: 9696
Martin Ratio Rank

GD
GD Risk / Return Rank: 7373
Overall Rank
GD Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
GD Sortino Ratio Rank: 7373
Sortino Ratio Rank
GD Omega Ratio Rank: 6969
Omega Ratio Rank
GD Calmar Ratio Rank: 7070
Calmar Ratio Rank
GD Martin Ratio Rank: 7878
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LGND vs. GD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and General Dynamics Corporation (GD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


LGNDGDDifference

Sharpe ratio

Return per unit of total volatility

3.53

1.17

+2.36

Sortino ratio

Return per unit of downside risk

3.92

1.91

+2.01

Omega ratio

Gain probability vs. loss probability

1.52

1.23

+0.29

Calmar ratio

Return relative to maximum drawdown

9.23

1.68

+7.54

Martin ratio

Return relative to average drawdown

23.23

5.90

+17.33

LGND vs. GD - Sharpe Ratio Comparison

The current LGND Sharpe Ratio is 3.53, which is higher than the GD Sharpe Ratio of 1.17. The chart below compares the historical Sharpe Ratios of LGND and GD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


LGNDGDDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.53

1.17

+2.36

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.35

0.70

-0.35

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.16

0.51

-0.35

Sharpe Ratio (All Time)

Calculated using the full available price history

0.11

0.57

-0.46

Drawdowns

LGND vs. GD - Drawdown Comparison

The maximum LGND drawdown since its inception was -93.34%, which is greater than GD's maximum drawdown of -75.67%. Use the drawdown chart below to compare losses from any high point for LGND and GD.


Loading charts...

Drawdown Indicators


LGNDGDDifference

Max Drawdown

Largest peak-to-trough decline

-93.34%

-75.67%

-17.67%

Max Drawdown (1Y)

Largest decline over 1 year

-14.07%

-14.53%

+0.46%

Max Drawdown (3Y)

Largest decline over 3 years

-37.25%

-22.55%

-14.70%

Max Drawdown (5Y)

Largest decline over 5 years

-70.11%

-22.55%

-47.56%

Max Drawdown (10Y)

Largest decline over 10 years

-81.94%

-51.63%

-30.31%

Current Drawdown

Current decline from peak

-14.61%

-7.83%

-6.78%

Average Drawdown

Average peak-to-trough decline

-44.57%

-15.61%

-28.96%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.57%

4.13%

+1.44%

Volatility

LGND vs. GD - Volatility Comparison

Ligand Pharmaceuticals Incorporated (LGND) has a higher volatility of 14.22% compared to General Dynamics Corporation (GD) at 5.09%. This indicates that LGND's price experiences larger fluctuations and is considered to be riskier than GD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LGNDGDDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.22%

5.09%

+9.13%

Volatility (6M)

Calculated over the trailing 6-month period

27.82%

17.03%

+10.79%

Volatility (1Y)

Calculated over the trailing 1-year period

36.72%

20.85%

+15.87%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

44.07%

20.38%

+23.69%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

45.38%

22.69%

+22.69%

Dividends

LGND vs. GD - Dividend Comparison

LGND has not paid dividends to shareholders, while GD's dividend yield for the trailing twelve months is around 1.81%.


PositionTTM20252024202320222021202020192018201720162015
GD
General Dynamics Corporation
1.81%1.76%2.12%2.01%2.00%2.24%2.90%2.26%2.31%1.61%1.72%1.96%
LGND
Ligand Pharmaceuticals Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

LGND vs. GD - Financials Comparison

This section allows you to compare key financial metrics between Ligand Pharmaceuticals Incorporated and General Dynamics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
51.72M
13.48B
(LGND) Total Revenue
(GD) Total Revenue
Values in USD except per share items

LGND vs. GD - Profitability Comparison

The chart below illustrates the profitability comparison between Ligand Pharmaceuticals Incorporated and General Dynamics Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
10.5%
Portfolio components
LGND - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported a gross profit of 0.00 and revenue of 51.72M. Therefore, the gross margin over that period was 0.0%.

GD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, General Dynamics Corporation reported a gross profit of 1.42B and revenue of 13.48B. Therefore, the gross margin over that period was 10.5%.

LGND - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported an operating income of 17.37M and revenue of 51.72M, resulting in an operating margin of 33.6%.

GD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, General Dynamics Corporation reported an operating income of 1.42B and revenue of 13.48B, resulting in an operating margin of 10.5%.

LGND - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported a net income of -13.35M and revenue of 51.72M, resulting in a net margin of -25.8%.

GD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, General Dynamics Corporation reported a net income of 1.13B and revenue of 13.48B, resulting in a net margin of 8.4%.


Frequently Asked Questions


LGND and GD have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

LGND has higher volatility (14.22%) compared to GD (5.09%). In terms of maximum drawdown, LGND dropped -93.34% vs GD's -75.67%.

LGND currently has the higher Sharpe Ratio (3.53 vs 1.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LGND and GD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer